ClinicaliQ Trial Snapshot
- An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body’s Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis — Recruiting • Phase I • Gastroenterology • NCT07665723.
- Early trial testing whether afimkibart affects how the body breaks down common medicines in ulcerative colitis patients.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the disease-drug-drug interaction (DDDI) potential of afimkibart (also known as RO7790121). This will be assessed by the characterization of the pharmacokinetics (PK) of cytochrome P450 (CYP) enzyme substrates alone and after administration of afimkibart in participants with moderately to severely active ulcerative colitis (UC). Conditions: Active Ulcerative Colitis Interventions: Afimkibart, Caffeine, Warfarin, Omeprazole, Dextromethorphan, Midazolam, Vitamin K Lead Sponsor: Hoffmann-La Roche Planned Enrollment: 25 participants